DC-SIGN antagonists were designed combining one selective monovalent glycomimetic ligand with trivalent dendrons separated by a rigid core of controlled length. The design combines multiple multivalency effects to achieve inhibitors of HIV infection, which are active in nanomolar concentration.
Ordanini, S., Varga, N., Porkolab, V., Thépaut, M., Belvisi, L., Bertaglia, A., et al. (2015). Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: Ligand presentation using molecular rods. CHEMICAL COMMUNICATIONS, 51(18), 3816-3819 [10.1039/c4cc09709b].
Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: Ligand presentation using molecular rods
Palmioli, Alessandro;
2015
Abstract
DC-SIGN antagonists were designed combining one selective monovalent glycomimetic ligand with trivalent dendrons separated by a rigid core of controlled length. The design combines multiple multivalency effects to achieve inhibitors of HIV infection, which are active in nanomolar concentration.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
c4cc09709b.pdf
accesso aperto
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Licenza:
Creative Commons
Dimensione
1.89 MB
Formato
Adobe PDF
|
1.89 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
